These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15810141)

  • 21. Advances in management of bone disease in breast cancer.
    Walkington L; Coleman RE
    Bone; 2011 Jan; 48(1):80-7. PubMed ID: 20621652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-induced bone diseases.
    Ogata E
    Eur J Cancer; 1998 Feb; 34(2):209. PubMed ID: 9741322
    [No Abstract]   [Full Text] [Related]  

  • 23. [Zoledronic acid in the treatment of prostate cancer].
    Conti G
    Minerva Urol Nefrol; 2005 Dec; 57(4):313-7. PubMed ID: 16247352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skeletal disorders in malignant disease.
    Kochersberger GG; Lyles KW
    Clin Geriatr Med; 1987 Aug; 3(3):561-74. PubMed ID: 3308050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The if's, and's, or but's regarding bisphosphonates for prostate cancer.
    Wilt TJ; Ensrud KE
    J Natl Cancer Inst; 2007 May; 99(10):744-5. PubMed ID: 17505065
    [No Abstract]   [Full Text] [Related]  

  • 26. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proceedings and abstracts of the VII International Meeting on Cancer Induced Bone Disease, June 2008, Edinburgh, UK.
    Cancer Treat Rev; 2008; 34 Suppl 1():S1-86. PubMed ID: 18788088
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
    Henk H; Teitelbaum A; Kaura S
    Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR
    Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to "Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Results from three Canadian centers"(Int J Radiat Oncol Biol Phys 2009;75:193-197).
    Roos D
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):637; author reply 637. PubMed ID: 20832666
    [No Abstract]   [Full Text] [Related]  

  • 31. 8th Workshop on Cell Biology of Bone and Cartilage in Health and Disease. Davos, Switzerland, April 1-4, 2000. 5th Workshop on Bisphosphonates--From Laboratory to the Patient. Davos, Switzerland, April 5-7, 2000. Abstracts.
    Bone; 2000 Mar; 26(3 Suppl):1S-46S. PubMed ID: 10709610
    [No Abstract]   [Full Text] [Related]  

  • 32. [Value of bone gammagraphy and pain in the follow-up of carcinoma of the prostate].
    Ruiz Cerdá JL; Llopis Minguez B; Server Pastor G; Vidal Moreno JF; Boronat Tormo F; Jiménez Cruz JF
    Arch Esp Urol; 1989; 42 Suppl 2():206-8. PubMed ID: 2639624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bubbly lesions of bone.
    Eisenberg RL
    AJR Am J Roentgenol; 2009 Aug; 193(2):W79-94. PubMed ID: 19620421
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of cancer-related bone pain].
    Borchard-Tuch C
    Med Monatsschr Pharm; 2016 Jan; 39(1):40-2. PubMed ID: 26975179
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone health in cancer patients - An important clinical issue.
    Weller D; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29105996
    [No Abstract]   [Full Text] [Related]  

  • 36. 7th Workshop on Cell Biology of Bone and Cartilage in Health and Disease and 4th Workshop on Bisphosphonates--from the Laboratory to the Patient. Davos, Switzerland, March 1998. Abstracts.
    Bone; 1998 Mar; 22(3 Suppl):1S-69S. PubMed ID: 9591086
    [No Abstract]   [Full Text] [Related]  

  • 37. The ageing skeleton.
    Corless D
    Practitioner; 1981 Dec; 225(1362):1775-85. PubMed ID: 7335609
    [No Abstract]   [Full Text] [Related]  

  • 38. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Roodman GD; Dougall WC
    Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Paraneoplastic syndromes in rheumatology].
    Godlewski S
    Cah Coll Med Hop Paris; 1966 May; 7(5):295-307. PubMed ID: 5941227
    [No Abstract]   [Full Text] [Related]  

  • 40. Sclerostin: a possible target for the management of cancer-induced bone disease.
    Gkotzamanidou M; Dimopoulos MA; Kastritis E; Christoulas D; Moulopoulos LA; Terpos E
    Expert Opin Ther Targets; 2012 Aug; 16(8):761-9. PubMed ID: 22762409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.